Jspr is a good buy now?

**Jasper Therapeutics (JSPR) is not currently a good buy.** Here's why:

1. **Financial Performance and Analyst Ratings**:
- JSPR's financials show a net loss of $14.58 million and a diluted EPS of $-0.97 as of Q2 2024. This indicates the company is not profitable at the moment.
- The company's 3-year revenue CAGR is not available, but the 3-year net income CAGR is 45.06% and the diluted EPS CAGR is 51.57%. These are strong indicators of growth potential, but they are not currently translating into positive revenue or net income.
- Analysts have given JSPR a consensus rating of "Buy" with an average price target of $73.00, which suggests some optimism about future prospects. However, the current stock price is significantly higher than this target, which could indicate that the positive news is already priced in.

2. **Technical Indicators**:
- The stock's technical indicators are not currently bullish. The RSI is at 19.81, which is in the oversold territory and could suggest a potential reversal or a buying opportunity if the stock is believed to be oversold.
- However, the MACD is at -0.45, and the KDJ is at 7.98, which are both negative and could indicate a bearish momentum. The Bollinger Bands are at 18.89, which could also suggest that the stock is currently in a bearish trend.
- The stock is currently trading below its 5-Day, 10-Day, and 20-Day moving averages, which could be seen as a bearish signal. However, it is trading above its 30-Day and 60-Day moving averages, which could suggest some short-term strength.

3. **Market Sentiment and Recent News**:
- The stock has seen a significant increase of 5.93% in the premarket session on positive data from the SPOTLIGHT study. However, this is not enough to change the overall negative view.
- The company has received positive attention from analysts, with Oppenheimer maintaining an "Outperform" rating and a high price target of $80.00. However, this is not a recent development and may not reflect the current sentiment.
- The stock has been volatile and has seen a significant increase in trading volume, which could be indicative of market interest or speculation.

4. **Risk Considerations**:
- The company is unprofitable and has a negative return on equity, return on assets, and return on tangible capital, which are red flags for investors.
- The company has a high debt-to-equity ratio, which could indicate financial risk.
- The stock has experienced significant volatility and has been subject to large price swings, which could be indicative of market uncertainty or speculation.

In conclusion, while there is potential for growth based on the company's product pipeline and the positive sentiment from analysts, the current financial performance, technical indicators, and market sentiment suggest that Jasper Therapeutics is not a good buy at this time. Investors should exercise caution and consider the high risk associated with the stock.